NCT03295396 2025-07-28ONC201 in Adults With Recurrent H3 K27M-mutant GliomaJazz PharmaceuticalsPhase 2 Terminated73 enrolled 13 charts 1 FDA
NCT01121588 2025-01-23Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)PfizerPhase 1 Terminated44 enrolled 22 charts 1 FDA
NCT02525692 2024-12-24Oral ONC201 in Adult Recurrent GlioblastomaJazz PharmaceuticalsPhase 2 Terminated84 enrolled 14 charts 1 FDA
NCT03640481 2024-12-12Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapySanofiPhase 2 Terminated159 enrolled 25 charts 1 FDA
NCT02013167 2024-03-05Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)AmgenPhase 3 Terminated405 enrolled 27 charts 1 FDA